Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D Kaplan

Showing results (821-830 of 861) with videos related to

Pageof 87
Sort By:
The Lancet. Oncology|November 18, 2022
5-year outcomes after stereotactic ablative body radiotherapy for primary renal cell carcinoma: an individual patient data meta-analysis from IROCK (the International Radiosurgery Consortium of the Kidney)Shankar Siva, Muhammad Ali, Rohann J M Correa, et al.
Clinical Lymphoma, Myeloma & Leukemia|March 18, 2015
A phase I study of targeted, dose-escalated intravenous busulfan in combination with etoposide as myeloablative therapy for autologous stem cell transplantation in acute myeloid leukemiaGabriel N Mannis, Charalambos Andreadis, Aaron C Logan, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 30, 2015
Changes in the influence of lymphoma- and HIV-specific factors on outcomes in AIDS-related non-Hodgkin lymphomaS K Barta, M S Samuel, X Xue, et al.
The Journal of Urology|September 6, 2016
Relief of Urinary Symptom Burden after Primary Prostate Cancer TreatmentPeter Chang, Meredith M Regan, Montserrat Ferrer, et al.
Molecular Cancer Therapeutics|April 22, 2024
Antitumor Activity of a Novel LAIR1 Antagonist in Combination with Anti-PD1 to Treat Collagen-Rich Solid TumorsBertha L Rodriguez, Jiawei Huang, Laura Gibson, et al.
Nature|June 11, 2010
Patient-specific induced pluripotent stem-cell-derived models of LEOPARD syndromeXonia Carvajal-Vergara, Ana Sevilla, Sunita L D'Souza, et al.
European Urology Oncology|July 10, 2024
Long-term Renal Function Outcomes After Stereotactic Ablative Body Radiotherapy for Primary Renal Cell Carcinoma Including Patients with a Solitary Kidney: A Report from the International Radiosurgery Oncology Consortium of the KidneyVivian S Tan, Rohann J M Correa, Andrew Warner, et al.
International Journal of Radiation Oncology, Biology, Physics|January 2, 2023
Five-Year Patient-Reported Outcomes in NRG Oncology RTOG 0938, Evaluating Two Ultrahypofractionated Regimens for Prostate CancerHimanshu R Lukka, Snehal Deshmukh, Deborah W Bruner, et al.
Blood|September 10, 2013
Treatment factors affecting outcomes in HIV-associated non-Hodgkin lymphomas: a pooled analysis of 1546 patientsStefan K Barta, Xiaonan Xue, Dan Wang, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|August 16, 2015
Patient-reported quality of life after stereotactic body radiotherapy (SBRT), intensity modulated radiotherapy (IMRT), and brachytherapyJoseph R Evans, Shuang Zhao, Stephanie Daignault, et al.
Pageof 87

Showing results (821-830 of 861) with videos related to

Sort By:
Pageof 87
The Lancet. Oncology|November 18, 2022
5-year outcomes after stereotactic ablative body radiotherapy for primary renal cell carcinoma: an individual patient data meta-analysis from IROCK (the International Radiosurgery Consortium of the Kidney)Shankar Siva, Muhammad Ali, Rohann J M Correa, et al.
Clinical Lymphoma, Myeloma & Leukemia|March 18, 2015
A phase I study of targeted, dose-escalated intravenous busulfan in combination with etoposide as myeloablative therapy for autologous stem cell transplantation in acute myeloid leukemiaGabriel N Mannis, Charalambos Andreadis, Aaron C Logan, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 30, 2015
Changes in the influence of lymphoma- and HIV-specific factors on outcomes in AIDS-related non-Hodgkin lymphomaS K Barta, M S Samuel, X Xue, et al.
The Journal of Urology|September 6, 2016
Relief of Urinary Symptom Burden after Primary Prostate Cancer TreatmentPeter Chang, Meredith M Regan, Montserrat Ferrer, et al.
Molecular Cancer Therapeutics|April 22, 2024
Antitumor Activity of a Novel LAIR1 Antagonist in Combination with Anti-PD1 to Treat Collagen-Rich Solid TumorsBertha L Rodriguez, Jiawei Huang, Laura Gibson, et al.
Nature|June 11, 2010
Patient-specific induced pluripotent stem-cell-derived models of LEOPARD syndromeXonia Carvajal-Vergara, Ana Sevilla, Sunita L D'Souza, et al.
European Urology Oncology|July 10, 2024
Long-term Renal Function Outcomes After Stereotactic Ablative Body Radiotherapy for Primary Renal Cell Carcinoma Including Patients with a Solitary Kidney: A Report from the International Radiosurgery Oncology Consortium of the KidneyVivian S Tan, Rohann J M Correa, Andrew Warner, et al.
International Journal of Radiation Oncology, Biology, Physics|January 2, 2023
Five-Year Patient-Reported Outcomes in NRG Oncology RTOG 0938, Evaluating Two Ultrahypofractionated Regimens for Prostate CancerHimanshu R Lukka, Snehal Deshmukh, Deborah W Bruner, et al.
Blood|September 10, 2013
Treatment factors affecting outcomes in HIV-associated non-Hodgkin lymphomas: a pooled analysis of 1546 patientsStefan K Barta, Xiaonan Xue, Dan Wang, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|August 16, 2015
Patient-reported quality of life after stereotactic body radiotherapy (SBRT), intensity modulated radiotherapy (IMRT), and brachytherapyJoseph R Evans, Shuang Zhao, Stephanie Daignault, et al.
Pageof 87